PURPOSE. Aspergillus and Fusarium molds cause blinding corneal infections as a consequence of ocular trauma and in association with contact lens wear. As these fungi require zinc for fungal growth, we examined the effect of atovaquone, a ubiquinone analog that disrupts zinc homeostasis, on fungal growth in vitro and in vivo.
A spergillus and Fusarium are filamentous molds that are ubiquitous in the environment; however, they can cause severe pulmonary, dermatologic, and systemic infections in patients with genetic or induced immune deficiencies, which frequently results in death from uncontrolled fungal growth. [1] [2] [3] [4] Fusarium species are also an important cause of contact lensrelated corneal infections in immune-competent individuals in the industrialized world, and Fusarium and Aspergillus corneal ulcers are common in developing countries following ocular injury and penetration of spores to the corneal stroma. [5] [6] [7] Fungal keratitis is painful, blinding, and frequently requires corneal transplantation. Also, current topical and systemic antifungal agents have limited efficacy, and there are several reports of resistance to commonly used drugs, such as azoles. [8] [9] [10] [11] Furthermore, many antifungal agents have severe side effects, including infusion reactions and nephrotoxicity. 12, 13 Overall, there is an unmet need for new drugs that target filamentous fungi, and that are safe and effective. 14, 15 We reported that the antimicrobial peptide calprotectin (S100A8/A9) produced by neutrophils inhibits Aspergillus fumigatus hyphal growth by successfully competing for free zinc and manganese, and that recombinant calprotectin inhibits experimental Aspergillus corneal infections. 16 These findings demonstrate that zinc uptake is a potential target for antifungal therapy.
In the current study, we examined the role of the ubiquinone analog atovaquone to target zinc homeostasis in Aspergillus keratitis. Atovaquone is a hydroxy-1,4-naphthoquinone that binds to cytochrome b and interferes with the electron transport chain and respiration in the protozoan parasites Plasmodium, Toxoplasma, Babesia, and Leishmania. [17] [18] [19] [20] [21] [22] Atovaquone is approved by the Food and Drug Administration for treatment of pneumonia caused by the pathogenic yeast Pneumocystis carinii and for malaria in combination therapy with proguanil hydrochloride (Malarone).
function and intracellular zinc storage in Aspergillus and Fusarium species, and that topical application inhibits hyphal growth in infected corneas.
MATERIALS AND METHODS

Fungal Strains and Growth Conditions
The sources of Fusarium and Aspergillus clinical isolates are listed in the Table above. The ATP Binding Cassette (ABC) transporter mutant HspA-Cdr1A and parent strains A. fumigatus were generously provided by Scott Moye-Rowley (University of Iowa). Fusarium strains were cultured at 308C on Sabouraud dextrose agar (SDA), whereas Aspergillus strains were cultured on SDA at 378C for 48 to 72 hours until conidiophores were generated. Conidia (spores) were harvested by scraping the plates, re-suspending conidia in sterile PBS and filtering through sterile gauze to remove hyphae.
In Vitro Hyphal Killing Assays
Conidia were plated at 5 3 10 3 /mL in 200 lL of Sabouraud Dextrose broth (SDB; Sigma-Aldrich, St. Louis, MO, USA). in black-walled 96-well plates with clear bottoms (Corning Inc., Corning, NY, USA), and incubated until germination (6 hours for Aspergillus, and 24 hours for the slower-growing Fusarium) as described. 25 For all experiments, Fusarium strains were cultured at 308C, whereas Aspergillus strains were cultured at 378C.
Atovaquone was purchased from Sigma-Aldrich and stock solution (25 mM) was prepared in dimethyl sulfoxide (DMSO) and stored at À208C. Amphotericin B solution was purchased from Sigma-Aldrich, itraconazole and voriconazole were purchased from Cayman Chemical (Ann Arbor, MI, USA), and 20 lg/mL stock solution was prepared in DMSO and stored at À208C.
Germinating conidia were incubated with 2-fold serial dilutions of atovaquone, Amphotericin B, itraconazole, or voriconazole (or DMSO control) in RPMI 1640. Incubation times were 18 hours for Aspergillus strains or 48 hours for Fusarium strains, which is when hyphae in RPMI alone reached maximal growth. Supernatants were then removed and the chitin-binding stain Calcofluor white (Sigma-Aldrich) was added at 50 lL per well for 10 minutes at room temperature (RT). Wells were washed three times in doubledistilled H 2 0 and raw fluorescent units (RFUs) were quantified using a Biotek (Winooski, VT, USA) Cytation 5 at 360/440 nM, as we described. 16 Images were acquired on the Cytation 5 using a 4 0 ,6-diamidino-2-phenylindole filter. Data are presented as the percentage of Calcofluor white fluorescence in RPMI with no drugs added (RFU þ drugs/RFU À drugs 3 100).
Mitochondrial Potential and ATP Measurement
Hyphae were incubated 2 hours with atovaquone, mitochondria inhibitor carbonyl cyanide m-chlorophenyl hydrazone (CCCP) or DMSO in RPMI 1640. RPMI was then removed and fresh RPMI 1640 (no phenol red) containing JC1 (2 lM) probe was added for 15 minutes, and fluorescence was quantified per the manufacturer's directions (MitoProbe JC1 Assay Kit; ThermoFisher Scientific, Waltham, MA, USA). JC-1 dye accumulates in healthy mitochondria (intact mitochondrial potential), indicated by a fluorescence emission shift from green (~529 nm) to red (~590 nm); consequently, mitochondrial depolarization is indicated by a decrease in the red/green fluorescence intensity ratio.
For ATP measurements, hyphae were treated with atovaquone or medium alone in 200 lL RPMI 1640 for 2 hours; 175 lL media was removed and 25 lL BacTiter-Glo Reagent (Promega, Madison, WI, USA) was added to the remaining 25 lL culture media and incubated for 10 minutes at RT. BacTiterGlo Reagent generates a luminescent signal proportional to the amount of ATP in a sample using a proprietary luciferase reagent (Promega). Luminescence was measured using the Cytation5 reader.
Fungal Viability Assay
Hyphae were treated with atovaquone or amphotericin B in RPMI plus 0.25 lM SYTOX green extracellular nucleic acid stain (ThermoFisher Scientific) where SYTOX reactivity is only detected in dead cells that have permeable membranes. Fluorescence (RFU) was recorded at 504/523 nm after incubation for 2 hours for Aspergillus or 8 hours for Fusarium.
Metal Shock and Zinc Measurements and Imaging
Aspergillus and Fusarium hyphae were incubated 2 hours with atovaquone, and the zinc chelator TPEN (Sigma-Aldrich) was added at indicated concentrations. To quantify total zinc in the hyphae, 2 lM Zinbo-5 (Santa Cruz Biotechnology, Dallas, TX, USA) in PBS or 25 lM Zinquin (Santa Cruz Biotechnology) in RPMI 1640 were added to wells for 15 minutes. Plates were washed, and fluorescence was read at 358/463 for Zinbo-5 or at 368/490 for Zinquin. For metal shock experiments in which high levels of metals are added to the cultures, conidia were grown to germination in SDB, washed, and RPMI þ/À atovaquone þ/À ZnSO 4 , MnSO 4 , or CuSO 4 (Sigma-Aldrich) was added. Hyphae were incubated 18 hours for Aspergillus or 48 hours for Fusarium. Fluorescence was quantified using Calcofluor white, as described above.
Acidic Vacuole Quantification
To quantify total acidified vacuoles, hyphae were incubated 2 hours with atovaquone, growth medium was removed, and 
Cytotoxicity Assay
Telomerase immortalized human corneal epithelial cells were plated in KGM Gold media (Lonza, Anaheim, CA, USA) and grown to confluency. Cells were incubated with atovaquone or DMSO vehicle for 24 hours, and cell death was measured by release of lactose dehydrogenase (LDH) into the media. LDH was quantified using CytoTox nonradioactive toxicity assay according to the manufacturer's directions (Promega). Cells were incubated with lysis buffer to measure total LDH, and cytotoxicity was measured as a percentage of total LDH.
Murine Model of Corneal Infection
Six-to 8-week old male and female C57BL/6 mice were purchased from the Jackson Laboratories (Bar Harbor, ME, USA). A. fumigatus and Fusarium conidia (50,000 in 2 lL PBS) were injected into the corneal stroma using a 33G Hamilton syringe as we described. 16, 26, 27 Atovaquone was diluted in a proprietary eye drop formulation provided by Alcon (Ft. Worth, TX, USA), and drug or vehicle only was dropped onto the ocular surface at 0, 2, and 6 hours postinfection (pi). After 24 hours, mice were imaged using a stereomicroscope. Corneal opacification was measured by image analysis using MetaMorph software (MetaMorph Inc., Nashville, TN, USA) as we previously described. 26 To measure colony forming units (CFUs), whole eyes were homogenized in sterile PBS using a Mixer Mill MM300 (Retsch, Haan, Germany), serial dilutions were plated on SDA, and CFUs were counted manually.
All animal experiments were approved by the Institutional Animal Care and Use Committee at Case Western Reserve University, and adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Statistical Analysis
All in vitro experiments were performed at least three times with three or more replicate wells for each condition. Corneal infection experiments had 5 mice per group, and were repeated twice. GraphPad Prism software (GraphPad, La Jolla, CA, USA) was used for all statistical analysis, which were performed on experimental replicates. Significance was determined using either a Student's t-test or ANOVA with Tukey post-analysis. Half maximal inhibitory concentration (IC50) values were calculated using the log(inhibitor) versus response equation, where 100% fungal mass indicates hyphal growth in media alone.
RESULTS
Atovaquone Inhibits Growth of Aspergillus Clinical Isolates
To determine whether atovaquone can inhibit growth of Aspergillus and Fusarium molds, conidia from Aspergillus and Fusarium clinical isolates from fungal keratitis patients were grown to the hyphal stages as described in Methods, incubated with atovaquone, and growth was quantified using Calcofluor white chitin stain. Both Aspergillus and Fusarium hyphae incubated with atovaquone exhibited significantly impaired hyphal growth compared with growth in RPMI media alone (Figs. 1A, 1B ). This concentration range was similar to that of other currently used polyene and azole antifungal agents, including voriconazole and amphotericin B ( Supplementary  Fig. S1A ). Fusarium oxysporum and Fusarium solani clinical isolates were 10-to 20-fold more sensitive to inhibition than Aspergillus (IC50 0.3-0.6 lM for Aspergillus, 0.001 to 0.06 lM for Fusarium [Table] ).
To differentiate between cell death and growth inhibition, A. fumigatus BP and F. oxysporum 8996 hyphae were incubated with atovaquone, and cell death was measured using the SYTOX green nucleic acid stain, which only binds to DNA of dead, permeable cells. We found significantly less Aspergillus and Fusarium viability (more SYTOX staining) following incubation with atovaquone compared with controls (Figs. 1C, 1D ), indicating that atovaquone actively kills Aspergillus and Fusarium hyphae.
Atovaquone Is Not Cytotoxic to Human Corneal Epithelial Cells
To examine if atovaquone is cytotoxic to mammalian cells, we incubated human corneal epithelial cells with increasing concentrations of atovaquone for 24 hours, and measured cell death by release of LDH into the culture medium compared with LDH in cells treated with lysis buffer (maximum lysis). These are the human HCE-T telomerase immortalized corneal epithelial cells generated by Robertson et al. 28 and which we have used extensively. 29, 30 As shown in Figure 2 , 10 lM and 100 lM atovaquone showed <20% LDH maximum release. Given that 1 lM atovaquone can inhibit Aspergillus and Fusarium growth, these data indicate that at the concentrations used, atovaquone has minimal cytotoxic activity on human corneal epithelial cells.
Atovaquone Reduces Intracellular Zinc Homeostasis in Aspergillus
Atovaquone was reported to reduce zinc levels in C. albicans yeast, and prior studies show that zinc is critical for Aspergillus growth and virulence. 24 To examine the effect of atovaquone on intracellular zinc levels, hyphae were grown to confluence, treated with atovaquone or the zinc chelator TPEN for 2 hours, and intracellular labile zinc was measured using Zinbo-5 and Zinquin fluorescent probes.
Representative images revealed bright Zinbo-5 staining in untreated A. fumigatus hyphae, but not following incubation with atovaquone or TPEN (Fig. 3A) . Quantification of Zinbo-5 and Zinquin fluorescence showed significantly less free zinc in A. fumigatus following incubation with atovaquone (Figs. 3B,  3C ).
To examine whether an exogenous source of zinc would rescue the effect of atovaquone on Aspergillus, hyphae were incubated with 1 lM atovaquone (which partially inhibits hyphal growth) together with an excess of ZnSO 4 . However, rather than restoring growth, the presence of excess zinc further inhibited A. fumigatus hyphal growth (Fig. 3D) , indicating that atovaquone increases hyphal susceptibility to metal toxicity (metal shock).
Despite the essential role for zinc in fungal metabolism, free zinc and other metals can be toxic to cells at higher levels. 31 Free metals are stored in specialized vacuoles, which require acidification by V-type ATPases to facilitate metal uptake. 32 To examine the effect of atovaquone on vacuolar acidification, we measured total acidic vacuoles using the pH-sensitive probe Lysosensor green, which has been used to measure zinc containing vacuoles in eukaryotic cells. 33 Aspergillus hyphae treated with atovaquone had significantly lower Lysosensor green fluorescence compared with RPMI controls (Fig. 3E) , indicating that the existing vacuoles are either less acidic or that there are fewer acidic compartments in treated organisms.
In contrast to Aspergillus, treatment of F. oxysporum 8996 hyphae with atovaquone significantly reduced labile zinc levels at 100 lM, but not at lower doses (Fig. 3F) . Furthermore, F. oxysporum hyphal growth was not impaired in the presence of atovaquone and excess zinc (Fig. 3G) . Treatment of F. oxysporum hyphae with atovaquone significantly reduced Lysosensor green fluorescence, thereby showing that atovaquone impaired vacuole acidification (Fig. 3H) .
Overall, these data indicate that in Aspergillus, atovaquone disrupts metal storage in vacuoles by inhibiting vacuolar acidification, which may explain the increased toxic effects of zinc. F. oxysporum shows less sensitivity to zinc modulation by atovaquone.
Aspergillus ABC Transporters Regulate Atovaquone and Azole Sensitivity ABC transporters in S. cerevisiae are essential for zinc storage in yeast, as loss of ABC transporters results in increased sensitivity to metal toxicity. 34 Furthermore, ABC transporters mediate resistance to azoles, 35 and atovaquone inhibits ABC transporter activity in mammalian cells. 36 To examine the role of ABC transporters on atovaquone and azole sensitivity of filamentous fungi, we used an A. Fumigatus mutant that overexpresses the ABC transporter Crd1A (abcA), which we predict will be more resistant to drugs that target ABC transporters. Parent and mutant strains were incubated with partially inhibitory doses of atovaquone alone or together with voriconazole or itraconazole, and growth was measured compared with the parent strain.
As shown in Figure 4A , atovaquone plus voriconazole was more effective than either drug alone in inhibiting growth of the parent Aspergillus strain. However, the Crd1 overexpressing mutant hspA-abcA strain showed increased resistance to atovaquone either alone or in combination with voriconazole. Similar results were found in separate experiments in which both strains were incubated with atovaquone alone or in combination with itraconazole (Fig. 4B) .
These data indicate that Aspergillus ABC transporters regulate sensitivity to atovaquone and azoles, and imply that (C, D) A. fumigatus BP or F. oxysporum 8996 were incubated in RPMI þ/À ATV in the presence of SYTOX Green, which measures extracellular nucleic acids. Fluorescence was measured after 2 hours, and percent viability was calculated as (fluorescence in RPMI only/ fluorescence þ ATV) 3 100. Experiments were performed at least three times with three or more replicate wells for each condition. *P < 0.05; **P < 0.01; ***P < 0.001. Experiments were performed at least three times with three or more replicate wells for each condition. *P < 0.05; **P < 0.01; ***P < 0.001. FIGURE 4. ABC transporter overexpression reduces sensitivity to atovaquone (ATV) and azoles. (A, B) A. fumigatus parent, wild type (WT) strain or AbcA overexpressing strain hsp-AbcA were incubated in RPMI þ/À ATV þ/À voriconazole (A) or itraconazole (B) for 18 hours and fungal mass was measured using Calcofluor chitin stain. % Fungal mass ¼ (Growth in ATV and/or azole /Growth in RPMI only) 3 100. Experiments were performed three times with three replicate wells for each condition. *P < 0.05; **P < 0.01; ***P < 0.001. atovaquone potentially disrupts metal storage in A. fumigatus by inhibiting ABC transporter activity.
Atovaquone Disrupts Mitochondrial Potential and ATP Production
The reported mechanism of action of atovaquone on Plasmodium is disruption of mitochondrial function. 21, 22 Therefore, we examined the effect of atovaquone on mitochondrial function and ATP production in fungi. A. fumigatus and F. oxysporum hyphae were incubated 2 hours with 100 lM atovaquone, and mitochondrial potential was measured using a MitoProbe with CCCP as a control mitochondrial inhibitor, as described in Materials and Methods.
We found that the mitochondrial potential was significantly reduced following incubation with atovaquone (Figs. 5A, 5B ). The effect of atovaquone was similar to that of CCCP, a wellcharacterized inhibitor of mitochondrial potential. Similarly, A. fumigatus and F. oxysporum ATP production was significantly lower in atovaquone-treated hyphae compared with untreated controls (Figs. 5C, 5D) .
Together, these data show that atovaquone also inhibits mitochondrial function and ATP production, resulting not only in inhibition of fungal growth, but also increased hyphal death.
Atovaquone Inhibits Hyphal Growth and Disease in a Murine Model of Corneal Infection
To examine the effect of atovaquone on Aspergillus and Fusarlium keratitis, we used a well-characterized model in which corneas are infected intrastromally with A. fumigatus or F. oxysporum dormant conidia. 26, 27 Atovaquone (50 mM in 2 lL) was applied topically at 0, 2, and 6 hours pi. Mice were euthanized after 24 hours, corneas were imaged for opacification, and CFUs in whole eyes were quantified. Our prior studies showed that the level of corneal opacity corresponds to neutrophil infiltration and live hyphae, that neutrophil recruitment to the cornea peaks at 24 hours, and that there is a strong correlation between CFUs and fungal mass in the cornea. 16, [25] [26] [27] Figures 6A-D show significantly less corneal disease in A. fumigatus-or F. oxysporum-infected corneas treated with atovaquone compared with untreated, infected corneas. CFUs per cornea were also significantly lower in atovaquone-treated corneas (Figs. 6E, 6F) . Although Fusarium grows slower in vitro, CFU and corneal opacity scores of F. oxysporum were similar to that of A. fumigatus, indicating that they grow at a similar rate in vivo.
These findings clearly demonstrate that atovaquone is effective in fungal keratitis.
DISCUSSION
Fungal keratitis caused by filamentous molds is a devastating corneal infection that can lead to pain, permanent blindness, and in severe cases loss of the eye. The limited number of antifungal drugs and increasing resistance to currently used agents indicates that new antifungal drugs are needed. In the current study, we demonstrate that atovaquone is effective in reducing growth of the pathogenic molds Fusarium and Aspergillus in vitro, and in reducing corneal disease and fungal burden in a murine model of fungal keratitis.
Atovaquone is an analog of ubiquinone/Coenzyme Q, which transfers electrons from dehydrogenases to cytochromes in the electron transport chain. 37 Atovaquone competitively inhibits coenzyme Q activity and collapses the mitochondrial membrane potential in Plasmodium. 37, 38 Although ATP levels are not reduced in atovaquone-treated Plasmodium, ATP levels in P. carinii yeast were significantly decreased following atovaquone treatment, 39, 40 indicating that atovaquone has more than one mechanism of action, and that the mechanisms may differ among pathogens. Atovaquone . Atovaquone disrupts mitochondrial potential and ATP production. A. fumigatus BP or F. oxysporum 8996 incubated 2 hours in RPMI þ/À ATV or CCCP, and mitochondrial potential was measured using the JC-1 probe (A, B). ATP was measured using the luminescent BacTiter-Glo Reagent (C, D). JC-1 and ATP were normalized to RPMI alone (100%). Experiments were performed at least three times with three or more replicate wells for each condition. *P < 0.05; **P < 0.01; ***P < 0.001. inhibits P. carinii growth at 0.3 to 3.0 lM, compared with 10 to 100 nM required for Plasmodium. 39, 40 In the current study, we demonstrate that atovaquone inhibits the growth of Aspergillus in a similar range as P. carinii (IC50 0.294-0.5 lM), whereas growth inhibition for Fusarium was detected at much lower levels, similar to Plasmodium (IC50 0.001-0.046 lM).
We also found that atovaquone reduces both mitochondrial membrane potential and ATP production in Aspergillus and Fusarium. In addition to directly targeting oxidative phosphorylation through inhibition of electron transport, atovaquone was reported to disrupt zinc homeostasis in an S. cerevisiae reporter system and in the pathogenic yeast C. albicans, although no mechanism was identified. 24 Zinc is essential for the catalytic activity of some 300 enzymes, and therefore contributes to growth and survival of microbial pathogens. 41 We and others 16, 42 reported that blocking zinc uptake with the antimicrobial peptide calprotectin (S100A8/9) inhibits growth of Aspergillus and other fungal pathogens, and that zinc acquisition is essential for Aspergillus virulence in corneal and pulmonary infections.
Although zinc is required for hyphal growth, divalent cations such as Zn 2þ are toxic to cells if not effectively stored within the cell. 41 Mislocalization of metals in the cytosol or other cellular compartments can be detrimental to cells in part by replacing iron in Fe-S centers of enzymes, and by interfering with mitochondrial activity. 41 Yeast cells have a specific storage vacuole that is required for zinc homeostasis, and which mediates transition metal uptake through Zrc1p in exchange for H þ ions. V-type ATPases maintain the vacuole acidification required for nontoxic storage of zinc and other metals, 41 and A. fumigatus ZrcA is the putative orthologue of Zrc1p. 43 In the current study, we demonstrate using Zinbo-5 and Zinquin dyes that labile (free vacuolar) Zn 2þ is present in untreated A. fumigatus hyphae, but is decreased following incubation with atovaquone. Further, addition of excess Zn 2þ does not rescue growth, but instead leads to increased fungal killing, suggesting that atovaquone increases the toxicity of Zn 2þ , possibly by blocking proper storage of metals within the cell. Overall, Fusarium was found to be less sensitive to zinc toxicity, which may indicate an alternate mechanism of metal regulation in this organism. It is possible that in Fusarium, atovaquone primarily affects mitochondrial function rather than zinc homeostasis.
We found that atovaquone reduced acidic compartments in the hyphae, likely vacuoles, thereby supporting a role for atovaquone in inhibiting V-type ATPases. This effect could be due to reduced overall ATP levels, or to a direct inhibitory effect of atovaquone on V-type ATPases. In support of this, Vtype ATPase-deficient S. cerevisiae yeast and Aspergillus nidulans exhibit defects in growth and vacuolar acidification, and are susceptible to metal shock. 44 V-type ATPases have therefore been proposed as a therapeutic target for antifungal drug development. 44, 45 In addition to V-type ATPases, the ABC G-family transporters of S. cerevisiae Pdr18p, Pdr5p, and Pdr15p were shown to interact with zinc transporters Zrtp and Zrc1p, which transport zinc across the plasma membrane and vacuolar membrane, respectively.
34 Pdr15 and to a lesser extent pdr5 and Pdr18 mutant yeast strains exhibited heightened sensitivity to zinc shock, indicating that ABC transporters are also essential for normal zinc homeostasis, including Zrc1p-mediated zinc storage in vacuoles. 34 A. fumigatus homologs of Zrt1p and Zrc1p, termed ZrfA and ZrcA, have been identified. 43, 46 Recently, it was reported that atovaquone inhibits ABC transporter BCRP/ABCG2 activity in HEK293 cells at 0.23 lM. 36 However, it has yet to be determined if atovaquone directly affects fungal ABC transporter activity. Enhancing metal sensitivity of pathogens could be a valuable tool due to recent development of metal-based antimicrobial agents, such as QBP, a form of 8-hydroxyquinolone that concentrates copper in the macrophage phagosome and enhances killing of Cryptococcus neoformans. 47 ABC transporters in Aspergillus and Fusarium are also implicated in azole resistance, including the A. fumigatus ABC transporters AbcA and AbcB, which have high sequence similarity to S. cerevisiae Pdr5. 35 Also, Fusarium graminearum ABC transporters ABC1, 3 and 4 contribute to azole resistance and virulence in plant hosts. 48 Given that atovaquone potentially inhibits ABC transporters, it could increase sensitivity to currently used azole drugs if used in combination. Consistent with this possibility, we show in the current study that fungi treated with atovaquone together with either itraconazole or voriconazole have a greater inhibitory effect on fungal growth than either atovaquone or azole alone. Further, the synergistic effect of atovaquone does not occur when an ABC transporter is overexpressed, as in the hspA-abcA mutant, indicating that atovaquone may also affect ABC transporter activity. These findings show that atovaquone increases the effectiveness of azoles, and indicates that combination therapy could be an effective treatment, particularly in the case of azole-resistant fungi. Although human cells also possess ABC transporters, atovaquone has a good safety profile and, as noted above, is widely used therapeutically.
Although given before infection, and at higher concentrations than required in vitro, our findings provide a proof of concept that atovaquone can be used to treat filamentous fungal infections, as we demonstrated that treatment of Aspergillus-or Fusarium-infected corneas with atovaquone reduced fungal burden and corneal opacification. Current antifungal drugs used in keratitis patients, such as natamycin, are given by topical delivery. Although topical delivery to and penetration of drug into the cornea are much less efficient, particularly with a hydrophobic drug such as atovaquone, new delivery methods are under investigation, including cyclodextrin compounds, which form binding pockets for lipophilic drugs to facilitate distribution and release, and have been shown to improve ocular delivery of voriconazole. 49 These findings will enable topical use at much lower concentrations than used here. Furthermore, new technologies, including contact lens release and ocular ''nanowafers,'' are also likely to improve ocular drug delivery and increase effectiveness. 50, 51 Atovaquone is currently dosed orally for malaria and P. carinii infections, and the effective range of atovaquone against filamentous fungi we demonstrate is well below steadystate plasma concentrations measured in patients (40-82 lM) 23 ; therefore, it is possible to reach inhibitory concentrations in plasma in vivo following oral administration. However, it is unclear whether oral drug delivery would result in high enough levels in the cornea. One indication that atovaquone can reach the cornea is that lipophilic drugs, such as atovaquone, when taken orally, can accumulate in the basal corneal epithelium. 52 Although this is associated with a corneal epithelium defect, symptoms are typically minor and resolve with cessation of treatment. Consistent with those reports, we also show that atovaquone has no cytotoxic effect on the viability of human corneal epithelial cells. In summary, we show that atovaquone directly kills and inhibits growth of filamentous fungi through at least two mechanisms. Firstly, atovaquone acts on the mitochondria to inhibit electron transport and reduce the mitochondrial potential, resulting in decreased ATP production and cell death. Secondly, atovaquone disrupts metal homeostasis either directly by inhibiting ABC transporters that are required for nontoxic storage of metal, or indirectly through reducing ATP levels, resulting in impaired V-type ATPase-mediated vacuolar acidification and sequestration of zinc. This results in the presence of free zinc in the cytosol, where it disrupts enzyme function and induces oxidative stress. 53 These studies show that atovaquone is a potential new therapy for filamentous fungal infections when given either alone or together with azoles. Filamentous fungi, especially Aspergillus species, also cause opportunistic lung and systemic infections in human immunodeficiency virus-infected and other immune-compromised individuals; therefore, in addition to keratitis patients, atovaquone may be a useful drug for these patients. Furthermore, these studies indicate that fungal metal homeostasis, V-type ATPases, and ABC transporters represent new targets for development of antifungal agents.
